The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Treatment of stimulant use disorder: A systematic review of reviews
Open accessAbstract
AIMS: Stimulant use disorder contributes to a substantial worldwide burden of disease, although evidence-based treatment options are limited. This systematic review of reviews aims to: (i) synthesize the available evidence on both psychosocial and pharmacological interventions for the treatment of stimulant use disorder; (ii) identify the most effective therapies to guide clinical practice, and (iii) highlight gaps for future study. METHODS: A systematic database search was conducted to identify systematic reviews and meta-analyses. Eligible studies were those that followed standard systematic review methodology and assessed randomized controlled trials focused on the efficacy of interventions for stimulant use disorder. Articles were critically appraised using an assessment tool adapted from Palmeteer et al. and categorized for quality as 'core' or 'supplementary' reviews. Evidence from the included reviews were further synthesized according to pharmacological or non-pharmacological management themes. RESULTS: Of 476 identified records, 29 systematic reviews examining eleven intervention modalities were included. The interventions identified include: contingency management, cognitive behavioural therapy, acupuncture, antidepressants, dopamine agonists, antipsychotics, anticonvulsants, disulfiram, opioid agonists, N-Acetylcysteine, and psychostimulants. There was sufficient evidence to support the efficacy of contingency management programs for treatment of stimulant use disorder. Psychostimulants, n-acetylcysteine, opioid agonist therapy, disulfiram and antidepressant pharmacological interventions were found to have insufficient evidence to support or discount their use. Results of this review do not support the use of all other treatment options. CONCLUSIONS: The results of this review supports the use of contingency management interventions for the treatment of stimulant use disorder. Although evidence to date is insufficient to support the clinical use of psychostimulants, our results demonstrate potential for future research in this area. Given the urgent need for effective pharmacological treatments for stimulant use disorder, high-quality primary research focused on the role of psychostimulant medications for the treatment of stimulant use disorder is needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Cochrane reviews have consistently highlighted the insufficiency of evidence to establish the effectiveness of certain psychotherapies for various SUDs, whether accompanied by comorbidity or not.”
From Navigating the Complex Intersection of Substance Use and Psychiatric Disorders: A Comprehensive Review (2024) · cites this paper as [48]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Evidence-based strategies, including contingency management (CM), cognitive-behavioral therapy (CBT), dialectical behavior therapy (DBT), motivational interviewing (MI), acceptance and commitment therapy (ACT), and family-based interventions, have demonstrated their effectiveness in reducing substance use and enhancing treatment outcomes”
From Navigating the Complex Intersection of Substance Use and Psychiatric Disorders: A Comprehensive Review (2024) · cites this paper as [48]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“An example of this shortfall is the inadequacy of high-quality research regarding the effectiveness of CBT in the treatment of stimulant use disorders [47,48,58].”
From Navigating the Complex Intersection of Substance Use and Psychiatric Disorders: A Comprehensive Review (2024) · cites this paper as [48]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence
Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002209.pub2 · Cited by 1,654
Methodology in conducting a systematic review of systematic reviews of healthcare interventions
Smith, V., Devane, D., Begley, C. M., & Clarke, M. (2011) · BMC Medical Research Methodology · doi:10.1186/1471-2288-11-15 · Cited by 1,227
Polysubstance use: diagnostic challenges, patterns of use and health
Connor, J. P., Gullo, M. J., White, A., & Kelly, A. B. (2014) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000069 · Cited by 461
Management of opioid use disorders: a national clinical practice guideline
Bruneau, J., Ahamad, K., Goyer, M.-È., Poulin, G., Selby, P., Fischer, B., Wild, T. C., & Wood, E. (2018) · Canadian Medical Association Journal · doi:10.1503/cmaj.170958 · Cited by 412
Self-citationPeirce, J. M., Petry, N. M., Stitzer, M. L., Blaine, J., Kellogg, S., Satterfield, F., Schwartz, M., Krasnansky, J., Pencer, E., Silva-Vazquez, L., et al. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.2.201 · Cited by 304 · cited 2×
“In a trial by Peirce et al., the intervention was successful at just $1.46 per participant per day, rather than an average cost of $120 per day that has been previously reported [54].”
InfluentialDe Crescenzo, F., Ciabattini, M., D’Alò, G. L., De Giorgi, R., Del Giovane, C., Cassar, C., Janiri, L., Clark, N., Ostacher, M. J., & Cipriani, A. (2018) · PLOS Medicine · doi:10.1371/journal.pmed.1002715 · Cited by 274
Efficacy of antidepressants in substance use disorders with and without comorbid depression
Torrens, M., Fonseca, F., Mateu, G., & Farré, M. (2005) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2004.09.004 · Cited by 261 · cited 1×
“In those with comorbid depression (five RCTs), meta-analysis showed no significant reduction in cocaine use for SSRI (OR: 0.54, 95% CI: 0.74, 7.30) or non-SSRI (OR: 2.32, 95% CI: 0.74, 7.30) antidepressants [26].”
InfluentialDisulfiram for the treatment of cocaine dependence
Pani, P. P., Trogu, E., Vacca, R., Amato, L., Vecchi, S., & Davoli, M. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007024.pub2 · Cited by 255
A systematic review of cognitive and behavioural therapies for methamphetamine dependence
LEE, N. K., & RAWSON, R. A. (2008) · Drug and Alcohol Review · doi:10.1080/09595230801919494 · Cited by 255
Palmateer, N., Kimber, J., Hickman, M., Hutchinson, S., Rhodes, T., & Goldberg, D. (2010) · Addiction · doi:10.1111/j.1360-0443.2009.02888.x · Cited by 248 · cited 1×
“All reviews that met inclusion criteria were critically appraised using an instrument adapted from Palmateer et al. (2010) [11] and based on recommendations for appraisal of interventional studies developed by the Health Development Agency [12] (see Table 1).”
Benishek, L. A., Dugosh, K. L., Kirby, K. C., Matejkowski, J., Clements, N. T., Seymour, B. L., & Festinger, D. S. (2014) · Addiction · doi:10.1111/add.12589 · Cited by 242
Stimulant Abuse: Pharmacology, Cocaine, Methamphetamine, Treatment, Attempts at Pharmacotherapy
Ciccarone, D. (2011) · Primary Care: Clinics in Office Practice · doi:10.1016/j.pop.2010.11.004 · Cited by 200 · cited 1×
“Both cocaine and methamphetamine act to increase the availability of monoamines in the synapse, however cocaine acts as a reuptake inhibitor, whereas methamphetamine binds transporters at the pre-synaptic membrane and is exchanged to release more monoamine neurotransmitter into the synapse [59].”
Roozen, H. G., Boulogne, J. J., van Tulder, M. W., van den Brink, W., De Jong, C. A. J., & Kerkhof, A. J. F. M. (2004) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2003.12.006 · Cited by 183
Kirby, K. C., Benishek, L. A., Dugosh, K. L., & Kerwin, M. E. (2006) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2006.03.010 · Cited by 180 · cited 2×
“Barriers that have been identified in the literature include treatment providers viewing programs as too costly, difficult to implement, or not aligning with political or philosophical values [53].”
Substance User Treatment Dropout from Client and Clinician Perspectives: A Pilot Study
Palmer, R. S., Murphy, M. K., Piselli, A., & Ball, S. A. (2009) · Substance Use & Misuse · doi:10.1080/10826080802495237 · Cited by 170
Efficacy of interventions to combat tobacco addiction: Cochrane update of 2013 reviews
Hartmann-Boyce, J., Stead, L. F., Cahill, K., & Lancaster, T. (2014) · Addiction · doi:10.1111/add.12633 · Cited by 164
Glutamate Transporter GLT-1 as a Therapeutic Target for Substance Use Disorders
Roberts-Wolfe, D., & Kalivas, P. W. (2015) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527314666150529144655 · Cited by 160 · cited 1×
“It has also been hypothesized to be of use in treating cocaine use disorder by restoring glutamate transporter-1 (GLT-1), by clearing excess glutamate from the extrasynaptic space, thus restoring glutamatergic homeostasis that is impaired with chronic stimulant use [42, 51].”
Pharmacotherapy for methamphetamine/amphetamine use disorder—a systematic review and meta‐analysis
Chan, B., Freeman, M., Kondo, K., Ayers, C., Montgomery, J., Paynter, R., & Kansagara, D. (2019) · Addiction · doi:10.1111/add.14755 · Cited by 160
Pharmacotherapy for Cocaine Use Disorder—a Systematic Review and Meta-analysis
Chan, B., Kondo, K., Freeman, M., Ayers, C., Montgomery, J., & Kansagara, D. (2019) · Journal of General Internal Medicine · doi:10.1007/s11606-019-05074-8 · Cited by 150
Anticonvulsants for cocaine dependence
Minozzi, S., Cinquini, M., Amato, L., Davoli, M., Farrell, M., Pani, P. P., & Vecchi, S. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006754.pub4 · Cited by 141 · cited 1×
“…primary or secondary outcome measures, including dropout (17 studies, RR: 0.95, 95% CI: 0.86, 1.05), cocaine use (9 studies, RR: 0.92, 95% CI: 0.84, 1.02), and side effects as measured by the number of participants reporting at least one side effect (8 studies, RR: 1.39, 95% CI: 1.01, 1.9) [33].”
InfluentialStrickland, J. C., Havens, J. R., & Stoops, W. W. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.107592 · Cited by 139
Naltrexone and relapse prevention treatment for cocaine-dependent patients
Schmitz, J. M., Stotts, A. L., Rhoades, H. M., & Grabowski, J. (2001) · Addictive Behaviors · doi:10.1016/s0306-4603(00)00098-8 · Cited by 138
Efficacy of psychostimulant drugs for amphetamine abuse or dependence
Pérez‐Mañá, C., Cervelló, X. C., Torrens, M., Capellà, D., & Farré, M. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009695.pub2 · Cited by 136 · cited 2×
“The medication was well tolerated and adverse events were rare [49].”
Topiramate for the Treatment of Cocaine Addiction: A Randomized Clinical Trial
Johnson, B. A., Ait-Daoud, N., Wang, X.-Q., Penberthy, J. K., Javors, M. A., Seneviratne, C., & Liu, L. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.2295 · Cited by 133
Darke, S. G., Kaye, S. S., & Duflou, J. A. (2017) · Addiction · doi:10.1111/add.13897 · Cited by 125 · cited 1×
“North America however maintains the highest prevalence of methamphetamine use worldwide, at 2.1 percent of the population aged 15–64 [6]Australia has also seen rising rates of methamphetamine use with related-deaths having doubled between 2009 and 2015 [7].”
InfluentialAntidepressants for cocaine dependence and problematic cocaine use
Pani, P. P., Trogu, E., Vecchi, S., & Amato, L. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002950.pub3 · Cited by 124
Antipsychotic medications for cocaine dependence
Indave, B. I., Minozzi, S., Pani, P. P., & Amato, L. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006306.pub3 · Cited by 122
Topiramate for the treatment of methamphetamine addiction: a multi‐center placebo‐controlled trial
Elkashef, A. M., Kahn, R., Yu, E., Iturriaga, E., Li, S., Anderson, A., Chiang, N., Ait‐Daoud, N., Weiss, D., McSherry, F., et al. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03771.x · Cited by 122
Dopamine agonists for the treatment of cocaine dependence.
Minozzi, S., Amato, L., Pani, P., Solimini, R., Vecchi, S., Crescenzo, F. D., Zuccaro, P., & Davoli, M. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003352.pub4 · Cited by 110
Psychostimulant drugs for cocaine dependence
Castells, X., Cunill, R., Pérez-Mañá, C., Vidal, X., & Capellà, D. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007380.pub4 · Cited by 110 · cited 6×
“Similar results were reported by Castells et al. for bupropion, dexamphetamine, disulfiram and mazindol as adjunct therapy to opioid agonist therapy in dual opioid-cocaine use disorder, with an increase in sustained cocaine abstinence (RR 1.44, 95% CI 1.05, 1.98) [36].”
InfluentialDarke, S., Torok, M., Kaye, S., Ross, J., & McKetin, R. (2010) · Addiction · doi:10.1111/j.1360-0443.2009.02872.x · Cited by 106
Auricular acupuncture for cocaine dependence
Gates, S., Smith, L. A., & Foxcroft, D. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005192.pub2 · Cited by 100
Pettinati, H. M., Kampman, K. M., Lynch, K. G., Xie, H., Dackis, C., Rabinowitz, A. R., & O′Brien, C. P. (2008) · Addictive Behaviors · doi:10.1016/j.addbeh.2007.11.011 · Cited by 95
Ray, L. A., Bujarski, S., Courtney, K. E., Moallem, N. R., Lunny, K. F., Roche, D., Leventhal, A. M., SHOPTAW, S. J., Heinzerling, K. G., London, E. D., et al. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.83 · Cited by 79
Kishi, T., Matsuda, Y., Iwata, N., & Correll, C. U. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13r08525 · Cited by 77
Cognitive-behavioural treatment for amphetamine-type stimulants (ATS)-use disorders
Harada, T., Tsutomi, H., Mori, R., & Wilson, D. B. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011315.pub2 · Cited by 76 · cited 2×
“A systematic review by Harada et al. evaluating the effectiveness of CBT for amphetamine-type stimulant use disorder included two RCTs and was unable to determine the effectiveness of CBT due to poor quality data [21].”
Schumacher, J. E., Milby, J. B., Wallace, D., Meehan, D. C., Kertesz, S. G., Vuchinich, R. E., Dunning, J., & Usdan, S. (2007) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.75.5.823 · Cited by 70
The Effects of Naltrexone on Alcohol and Cocaine Use in Dually Addicted Patients
Oslin, D. W., Pettinati, H. M., Volpicelli, J. R., Wolf, A. L., Kampman, K. M., & O’Brien, C. P. (1999) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(98)00039-7 · Cited by 69
Cervelló, X. C., Kosten, T. R., Capellà, D., Vidal, X., Colom, J., & Casas, M. (2009) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990903108215 · Cited by 68 · cited 2×
“Adjunctive treatment options including indirect dopamine agonist therapy and CM were found to significantly improve cocaine abstinence [41].”
Sinclair, J., Chambers, S. E., Shiles, C. J., & Baldwin, D. S. (2016) · Drug Safety · doi:10.1007/s40264-016-0416-y · Cited by 67
García–Rodríguez, O., Secades‐Villa, R., Higgins, S. T., Hermida, J. R. F., Carballo, J. L., Perez, J. M. E., & Al‐Halabí, S. (2009) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0015963 · Cited by 66
Measures of outcome for stimulant trials: ACTTION recommendations and research agenda
Kiluk, B. D., Carroll, K. M., Duhig, A. M., Falk, D. E., Kampman, K. M., Lai, S., Litten, R. Z., McCann, D. J., Montoya, I. D., Preston, K. L., et al. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.11.004 · Cited by 66 · cited 2×
“Long-term cessation of use has traditionally been the primary goal of substance use treatment and abstinence measures have been the most commonly implemented standard outcomes in randomized controlled trials [61].”
Cohen‐Barak, O., Wildeman, J., van de Wetering, J., Hettinga, J., Schuilenga‐Hut, P. H. L., Gross, A., Clark, S., Bassan, M., Gilgun‐Sherki, Y., Mendzelevski, B., et al. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.450 · Cited by 64
Winhusen, T. M., Kropp, F. B., Lindblad, R., Douaihy, A. B., Haynes, L. F., Hodgkins, C. C., Chartier, K. G., Kampman, K. M., Sharma, G., Lewis, D. F., et al. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08862 · Cited by 61
Umbricht, A., DeFulio, A., Winstanley, E. L., Tompkins, D. A., Peirce, J., Mintzer, M. Z., Strain, E. C., & Bigelow, G. E. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.03.033 · Cited by 57
Bhatt, M., Zielinski, L., Baker-Beal, L., Bhatnagar, N., Mouravska, N., Laplante, P., Worster, A., Thabane, L., & Samaan, Z. (2016) · Systematic Reviews · doi:10.1186/s13643-016-0370-x · Cited by 56 · cited 3×
“Authors found no effect on treatment retention, but a small subgroup analysis suggested improvement with longer duration of psychostimulant treatment [37].”
Efficacy of Contingency Management for Cocaine Dependence Treatment: A Review of the Evidence
Schierenberg, A., van Amsterdam, J., van den Brink, W., & Goudriaan, A. E. (2012) · Current Drug Abuse Reviews · doi:10.2174/1874473711205040006 · Cited by 55 · cited 1×
“Schierenberg and colleagues evaluated CM in conjunction with standard treatment options for cocaine dependence, including CBT, pharmacotherapy and community reinforcement programs (CRA) [19].”
N-acetylcysteine for treating cocaine addiction – A systematic review
Echevarria, M. A. N., Reis, T. A., Capatti, G. R., Soares, V. S., da Silveira, D. X., & Fidalgo, T. M. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.02.024 · Cited by 55 · cited 3×
“Side effects were reported as mild and did not vary significantly between doses [42].”
Dürsteler, K. M., Berger, E.-M., Strasser, H., Caflisch, C., Mutschler, J., Herdener, M., & Vogel, M. (2015) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s50807 · Cited by 54
Comer, S. D., Mogali, S., Saccone, P. A., Askalsky, P., Martínez, D., Walker, E. A., Jones, J. D., Vosburg, S. K., Cooper, Z. D., Roux, P., et al. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.143 · Cited by 53
Singh, M., Keer, D., Klimas, J., Wood, E., & Werb, D. (2016) · Addiction · doi:10.1111/add.13328 · Cited by 51
Self-citationMurphy, S. M., McDonell, M. G., McPherson, S., Srebnik, D. S., Angelo, F., Roll, J. M., & Ries, R. K. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.05.004 · Cited by 50
Long-QT Syndrome Induced by the Antiaddiction Drug Ibogaine
Hoelen, D. W. M., Spiering, W., & Valk, G. D. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0804248 · Cited by 48
Farronato, N. S., Dürsteler‐MacFarland, K. M., Wiesbeck, G. A., & Petitjean, S. A. (2013) · Journal of Addictive Diseases · doi:10.1080/10550887.2013.824328 · Cited by 48
Alves, P., Sales, C. M. D., & Ashworth, M. J. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.05.049 · Cited by 45 · cited 1×
“However, the definition of recovery may vary based on individual patient goals, by feasibility within the study time period, and may not always include abstinence [62].”
Antipsychotic drugs in cocaine dependence: A systematic review and meta-analysis
Álvarez, Y., Pérez‐Mañá, C., Torrens, M., & Farré, M. (2013) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2012.12.013 · Cited by 39
Modafinil Treatment of Cocaine Dependence: A Systematic Review and Meta-Analysis
Sangroula, D., Motiwala, F., Wagle, B., Shah, V. C., Hagi, K., & Lippmann, S. (2017) · Substance Use & Misuse · doi:10.1080/10826084.2016.1276597 · Cited by 39
Effects of active anti-methamphetamine vaccination on intravenous self-administration in rats
Miller, M. L., Aarde, S. M., Moreno, A. Y., Creehan, K. M., Janda, K. D., & Taffe, M. A. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.06.014 · Cited by 38 · cited 1×
“These alternative therapies are beyond the scope of this review, although may warrant further investigation [73– 76].”
Anticonvulsant drugs in cocaine dependence: A systematic review and meta-analysis
Alvarez, Y., Farré, M., Fonseca, F., & Torrens, M. (2009) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2009.07.001 · Cited by 36
Cunningham, E. B., Jacka, B. P., DeBeck, K., Applegate, T. L., Harrigan, P. R., Krajden, M., Marshall, B. D. L., Montaner, J. S. G., Lima, V. D., Olmstead, A. D., et al. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.04.005 · Cited by 35
Self-citationFactors associated with hepatitis C viremia in a large cohort of HIV-infected and -uninfected women
Operskalski, E. A., Mack, W. J., Strickler, H. D., French, A. L., Augenbraun, M. H., Tien, P. C., Villacres, M. C., Spencer, L. Y., deGiacomo, M., & Kovács, A. (2008) · Journal of Clinical Virology · doi:10.1016/j.jcv.2007.08.021 · Cited by 34
Pérez-Mañá, C., Castells, X., Vidal, X., Casas, M., & Capellà, D. (2011) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2010.08.012 · Cited by 33
Uhlmann, S., DeBeck, K., Simo, A., Kerr, T. H., Montaner, J. S. G., & Wood, E. (2014) · American Journal on Addictions · doi:10.1111/j.1521-0391.2014.12123.x · Cited by 31
Self-citationEfficacy of acupuncture for cocaine dependence: a systematic review & meta-analysis
Mills, E. J., Wu, P., Gagnier, J. J., & Ebbert, J. O. (2005) · Harm Reduction Journal · doi:10.1186/1477-7517-2-4 · Cited by 30
Efficacy of Acupuncture for Treating Cocaine Addiction
Kim, Y.-H. “., Schiff, E., Waalen, J., & Hovell, M. (2005) · Journal of Addictive Diseases · doi:10.1300/j069v24n04_09 · Cited by 29
Rúnarsdóttir, V. Á., Hansdóttir, I., Tyrfingsson, Þ., Einarsson, M., Dugosh, K. L., Royer-Malvestuto, C., Pettinati, H. M., Khalsa, J. H., & WOODY, G. E. (2017) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000297 · Cited by 27
Pharmacotherapy: Quest for the quitting pill
Willyard, C. (2015) · Nature · doi:10.1038/522s53a · Cited by 23
Auricular acupuncture for cocaine dependence
Gates, S., FOXCROFT, D. R., & Smith, L. (2005) · doi:10.1002/14651858.cd005192 · Cited by 21
Polysubstance use patterns and novel synthetics: A cluster analysis from three U.S. cities
Elliott, L. C., Haddock, C. K., Campos, S., & Benoit, E. (2019) · PLoS ONE · doi:10.1371/journal.pone.0225273 · Cited by 19 · cited 1×
“Finally, polysubstance use is common [63, 64].”
Saddichha, S., Werker, G. R., Schütz, C. G., & Krausz, M. R. (2014) · International Journal of Offender Therapy and Comparative Criminology · doi:10.1177/0306624x14541661 · Cited by 12
Ze, L. (2020) · Journal of physiotherapy · doi:10.1016/j.jphys.2020.06.003 · Cited by 4
Research works printed but not linked: 3
- M Kelly, 2002, Methodological problems in constructing the evidence base in public health, Health Development Agency Public Health Evidence Steering Group Methodology Reference Group Starter Paper, 9
- S Ellis, 2003, HIV prevention: A review of reviews assessing the effectiveness of interventions to reduce the risk of sexual transmission: Evidence briefing
- Castells X, Kosten TR, Capella D, Vidal X, Colom J, Casas M. Efficacy of opiate maintenance therapy and adjunctive interventions for opioid dependence with comorbid cocaine use disorders: A systematic review and meta-analysis of controlled clinical trials.
Cited by
O’Donnell, J., Gladden, R. M., Mattson, C. L., Hunter, C. T., & Davis, N. L. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6935a1 · Cited by 245
“Supporting increased access to medications for opioid use disorder¶¶¶¶¶ and evidence-based treatments for stimulant use disorders (17) can help mitigate risks.”
BackgroundJones, C. M., Houry, D., Han, B., Baldwin, G., Vivolo‐Kantor, A., & Compton, W. M. (2022) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14688 · Cited by 202
Drug Overdose Mortality Among People Experiencing Homelessness, 2003 to 2018
Fine, D. R., Dickins, K. A., Adams, L. D., Nueces, D. D. L., Weinstock, K., Wright, J. D., Gaeta, J. M., & Baggett, T. P. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.42676 · Cited by 151
Racial/Ethnic and Geographic Trends in Combined Stimulant/Opioid Overdoses, 2007–2019
Townsend, T., Kline, D., Rivera‐Aguirre, A., Bunting, A. M., Mauro, P. M., Marshall, B. D. L., Martins, S. S., & Cerdá, M. (2021) · American Journal of Epidemiology · doi:10.1093/aje/kwab290 · Cited by 121
Kariisa, M., Seth, P., Scholl, L., Wilson, N. O., & Davis, N. L. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.109001 · Cited by 97
Metadata
- Authors
- Ronsley, C., Nolan, S., Knight, R., Hayashi, K., Klimas, J., Walley, A., Wood, E., & Fairbairn, N.
- Affiliations
- University of British Columbia (CA)
- Simon Fraser University (CA)
- Boston University (US)
- Corresponding author
- Fairbairn, Nadia
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2020-06-18
- Volume
- 15
- Issue
- 6
- Pages
- e0234809
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC7302911
- OpenAlex
- W3036747176
- Cited by
- 222
- References
- 76
- Citations by year
- 2026: 29 · 2025: 46 · 2024: 48 · 2023: 40 · 2022: 27 · 2021: 26 · 2020: 6
- FWCI
- 3.61
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Lenus, The Irish Health Repository (Dr Steevens Hospital Library) (submittedVersion)
- Arrow@dit (Dublin Institute of Technology) (submittedVersion, cc-by-nc-nd)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Research Repository UCD (University College Dublin) (submittedVersion, cc-by-nc-nd)
- Lenus, The Irish Health Repository (Dr Steevens Hospital Library) (submittedVersion, cc-by)
- Funders
- Michael Smith Foundation for Health Research
- St. Paul's Foundation
- Canada Research Chair in Addiction Medicine
- Canadian Institute of Health Research (MSH - 141971)
- University of British Columbia Steven Diamond Professorship in Addiction Care Innovation
- European Commission (701698)
- Collaboration for Leadership in Applied Health Research and Care - Greater Manchester (671 397968, 422332)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Social Sciences › Psychology › Clinical Psychology › Gambling Behavior and Treatments
- Keywords
- stimulant use disorder, cocaine dependence, treatment efficacy, contingency management, psychostimulants, N-acetylcysteine, opioid substitution therapy, disulfiram, antidepressants, dopamine agonists, antipsychotic drugs, antiepileptic drugs, acupuncture, cognitive behavioral therapy, psychosocial interventions, pharmacological interventions
- MeSH terms
- Central Nervous System Stimulants, Anticonvulsants, Antidepressive Agents, Humans, Antipsychotic Agents, Cognitive Behavioral Therapy, Dopamine Agonists, Substance-Related Disorders, Acupuncture
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
